AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

See the rest here:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh